Aventis Pharmaceuticals Inc.

Sanofi-a Ventis Deutschland Gmbh

Jean Merrill

Stefanie Keil

Wolfgang Wendler

Jochen Goerlitzer

Daniel Gerard McGarry

Karen Chandross

Patrick Bernardelli

Yulin Chiang

Baptiste Ronan

Maike Glien

Tahir Nadeem Majid

Corinne Terrier

Brian L Pedgrift

Nicola Collar

Thaddeus Nieduzak

Sharon Anne Jackson

Guyan Liang

Sam Rebello

Friederike Wirtz-Brugger

Corey Hopkins

Thaddeus R Nieduzak

Sam S Rebello

Daniel G Mcgarry

The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists

The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.  The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.

1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease

The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.  The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

The present invention relates to coumarins of the formula (I): that are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions and methods of using these compounds as inhibitors of nitric oxide synthase are described herein.

Coumarins as iNOS inhibitors

Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.

Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders

Growing community of inventors

Whippany, NJ, United States of America

Jean Merrill